Found 112 clinical trials
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)
The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the
- 4 views
- 28 Jan, 2022
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
daratumumab to increase efficacy and improve outcomes of patients in both the relapse refractory and newly diagnosed settings. Two large Phase 2 trails using lenalidomide and dexamethasone or bortezomib and
- 15 views
- 24 Jan, 2021
- 2 locations
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (Generate-Boost)
will be specifically targeted by a substance called bortezomib. The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of
- 5 views
- 14 Mar, 2022
- 2 locations
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can
- 0 views
- 02 Jan, 2022
- 1 location
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
(500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The treatment course would be repeated three months later.
- 8 views
- 21 Oct, 2021
- 1 location
Bortezomib Isatuximab Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients
This is a single-arm, open-label phase II study with a safety lead-in phase.
- 0 views
- 21 Nov, 2021
- 1 location
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma
- 0 views
- 15 Dec, 2021
- 1 location
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of
- 0 views
- 24 Mar, 2022
- 1 location
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)
An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly
- 0 views
- 10 May, 2022
- 1 location
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.
- 25 views
- 18 May, 2022
- 1 location